Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.27 CAD
Change Today 0.00 / 0.00%
Volume 0.0
As of 3:59 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

theralase technologies inc (TLT) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/23/14 - C$0.78
52 Week Low
10/6/14 - C$0.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

theralase technologies inc (TLT) Related Businessweek News

No Related Businessweek News Found

theralase technologies inc (TLT) Details

Theralase Technologies Inc. designs, develops, manufactures, and markets laser technology used in biostimulative and biodestructive clinical applications. The company operates in two divisions, Therapeutic Laser Technology and Photo Dynamic Therapy. It engages in the production, marketing, and distribution of TLC-1000 and TLC-2000 laser technology for the treatment of pain, neural muscular skeletal conditions, and wound healing. The company is also involved in the research, development, and commercialization of the patented and patent pending TLC-3000 Photo Dynamic Compound technology through pre-clinical scientific research, technology development, and clinical trials to destroy cancers for oncological applications, as well as bacteria for human, animal, and sterilization applications. In addition, it operates a full service medical rehabilitation clinic in Toronto, Ontario for training and education of health-care practitioners. The company sells its products to licensed healthcare practitioners in Canada, the United States, and internationally. Theralase Technologies Inc. has strategic partnerships with University Health Network, Ontario Centers of Excellence for Photonics, National Research Council of Canada, Virginia Tech, The Scripps Research Institute, Mayo Clinic, University of Buffalo, and JSS Medical Research. The company is headquartered in Toronto, Canada.

theralase technologies inc (TLT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$150.0K
Chief Financial Officer
Total Annual Compensation: C$115.0K
Compensation as of Fiscal Year 2013.

theralase technologies inc (TLT) Key Developments

Theralase Technologies Inc. Announces Earnings Results for the Six Months Ended June 30, 2015

Theralase Technologies Inc. announced earnings results for the six months ended June 30, 2015. For the period, the company's revenue decreased by 21% from the same period in 2014. In Canada, revenue increased 11% to CAD 562,890 from CAD 508,523, while US revenue decreased 54% from CAD 215,107 to CAD 99,343 and international revenue decreased 89% from CAD 136,807 to CAD 15,584. The net loss for the period was CAD 2,279,117 compared to a net loss for the same period in 2014 of CAD 689,726. The increase in net loss is due to increased investment in research and development, sales and marketing personnel and administrative personnel all related to the pending launch of the next generation therapeutic laser and the commencement of a Phase Ib clinical study for Non-Muscle Invasive Bladder Cancer in fourth quarter of 2015.

Theralase Technologies Inc. Achieves Near Complete Destruction of Bladder Cancer in an Animal Model

Theralase Technologies Inc. announced that it has achieved near complete destruction (~98%) of bladder cancer in an animal model. Theralase, in order to optimize the model, relocated it to Princess Margaret Cancer Center, University Health Network ("UHN") under the direction of Dr. Lothar Lilge, Senior Scientist, UHN and Dr. Arkady Mandel, Chief Scientific Officer ("CSO") of the Company. Optimization of both the formulation and purity of the lead drug, TLD-1433, by Sigma Aldridge Fine Chemicals ("SAFC") and the wavelength of laser light used to activate the drug by Theralase resulted in achieving the high cell kill to date. Bladder cancer is the 5th most prevalent cancer in the world (4th in men, 8th in women) resulting in 430,000 new cases worldwide and an estimated 91,000 deaths annually. There has been no new treatment developed for this disease in the last 16 years. The cost to treat a patient with this disease ranges from $100,000 to $200,000. The disease has an 80% recurrence rate. 70% of new bladder cancer cases are early stage disease affecting the inner lining of the bladder (urothelium) and are known as Non-Muscle Invasive Bladder Cancer ("NMIBC"). According to the latest clinical research, 25% of these patients will have a recurrence of the disease within 6 months and a total of 50% recur within 2 years. The standard of care currently is to surgically resect the bladder tumour followed by installation of a bacteria, known as Bacillus-Calmette Guérin ("BCG") into the bladder for high risk patients. The next course of action for these patients, where the standard of care was not effective, is to either repeat the same treatment (surgery and BCG therapy) or to surgically remove the bladder in its entirety with any associated lymph nodes and nearby organs. Theralase is developing an alternative therapy, known as Photo Dynamic Therapy ("PDT"), applicable for the 50% of patients or those who have relapsed within 2 years of treatment. In this form of treatment, Theralase's lead water-soluble PDT drug, TLD-1433, is instilled into the bladder via a plastic tube known as a catheter, allowed to be absorbed into the bladder cancer cells for approximately one hour and then subsequently laser light activated over a period of 30 minutes. The entire procedure could be performed in a surgical suite in less than 3 hours. Theralase is researching the destruction of the entire bladder tumour with only one treatment; however, subsequent treatments could be performed in the future if there ever was a recurrence. The worldwide market for bladder cancer treatment is estimated to be worth more than $20 billion annually, with half of this population having a need for an alternative to their standard of care within 2 years.

Theralase Technologies Inc. Announces Executive Appointments

Theralase Technologies Inc. announced that it has appointed an experienced sales and marketing team to launch its next generation therapeutic laser. David Smith, Director of Sales, David has demonstrated success in previous senior sales positions with Eli Lilly, Baxter and Philips Healthcare. Alan Chan, Director of Marketing, Alan was a pioneer in the creation of the medical aesthetics market, when he led the launch of Botox. Alan possesses the experience and vision to help Theralase command a dominant role in the therapeutic laser market with the launch of the TLC-2000.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TLT:CN C$0.27 CAD 0.00

TLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TLT.
View Industry Companies

Industry Analysis


Industry Average

Valuation TLT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 20.3x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERALASE TECHNOLOGIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at